Clinical Trial Detail

NCT ID NCT04195750
Title A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

clear cell renal cell carcinoma

Therapies

PT 2977

Everolimus

Age Groups: adult senior

No variant requirements are available.